i-Newsletter 2022 autumn
Braizon Therapeutics ,Inc.
advances into the Hello Tomorrow Challenge 2022 Global Summit!

With all finalists of Hello Tomorrow Asia Pacific 2022 / Hello Tomorrow JapanOn October 5th, 2022, the Hello Tomorrow APAC held its Challenge 2022, a pitch contest in English targeting Japan
2022 SUMMIT in Singapore. Dr. Philip Davy, President and based startups, and held in Japan on September 13th, winning
CEO of Braizon Therapeutics ,Inc. took part in the event as their fast track for the Hello Tomorrow APAC Challenge2022.
one of the finalists of the Hello Tomorrow APAC challenge
Braizon Therapeutics ,Inc. located in KING SKYFRONT, was The Hello Tomorrow Global Summit, one of the largest deep
the Grand Winner out of fifteen finalists, winning their ticket tech events, is scheduled to be held from March 9th to 10th,
to become finalist of the Hello Tomorrow Global Challenge in 2023, in Paris. Withing the Global Summit is held the Hello
Tomorrow Global Challenge, one of the world’s most reParis, on March 2023.
nowned early-stage deep tech startups pitch contests. Every
Braizon Therapeutics ,Inc. is a start-up aiming for applying year, more than 4000 startups from 115 countries apply.
and commercializing "breakthrough technology for drug deliv- Around 800 of them are selected as Deep Tech Pioneers, asery to the brain."sessing the quality and impact of their technology. Around 80
It is the result of the joint research between Professor startups are selected to become finalists of the Global ChalKATAOKA Kazunori, Graduate Schools of Engineering and lenge.
Medicine, University of Tokyo (Currently Professor Emeritus The winners of the Global Challenge will win an equity-freeat The University of Tokyo), and Professor YOKOTA Taka- prize money: €100K for the Grand Winner, €30K for 2ndnori, Graduate School of Medical and Dental Sciences, Tokyo place and €20K for 3rd place. The 10 Track Winners will also
Medical and Dental University, medical and life science fields. receive in-kind prizes in the form of customized coaching sesFor treating CNS diseases, drugs need to be delivered to the sions provided by experts, and personal introductions withbrain, however as the brain has a biological barrier, it is ex- relevant investors and potential partners and clients.
tremely difficult to deliver drugs as necessary amount of treat- It is certain that Braizon Therapeutics’ technology will catchment. The solution “Brain Access” is trying to solve this probattention! Approximately 1,000
lem by using transferrin receptor ligand-modified micelles.
startups developing cutting-edge
Moreover, the technology is uniquely versatile; adapting totechnologies and over three hunvarious forms of drugs, low molecular weight compounds,
dred deep technology investors
nucleic acid drugs, etc. It demonstrates high delivery efficienand other active players involved
cy relative to dosage and thus expectations for commercializain Deep Tech are gathered. Yourtion are high.
support is very much appreciated.
Thank you!
Hello Tomorrow is a Paris-based organization with an extensive global network in deep tech, 6 hubs worldwide, including
Japan and Singapore, and more than 70 individuals in 30+
Braizon Therapeutics Co / Hellocountries. They support early-stage deep tech entrepreneurs
Tomorrow APAC Challenge 2022with impactful and disruptive technologies. They also promotesocial implementation of solutions and innovative technologies
Click here for Hello Tomorrowfor the modern society through R&D.
Global Challenge
Braizon Therapeutics applied to the Hello Tomorrow Japan

Visit by Economic and Commercial Office,Embassy of Spainand Spanish companies
On October 11th, Economic and Commercial Office, Embassy of Spain andSpanish companies visited KING SKYFRONT. The purpose of their visit
was to observe the current situation of a life-science, innovation eco-system
in Japan and get a hint for business collaboration with Japan through interaction with local institutions.
At the Innovation Center of NanoMedicine (iCONM), where they visited
first, they had a summary from Deputy Director Dr. Nagai about the efforts
for building an “In-body hospitals” by creating virus-sized smart machines.
Afterwards, they toured the facilities, focusing on the distinctive areas thathave been developed for the creation of open innovation.
At the National Institute of Health Sciences (NIHS), Dr. Homma, Deputy Director General, introduced the history of NIHS
and current efforts in regulatory science for pharmaceuticals, foods, and chemicals in living environment. Dr. Yamamoto,Director of Division of Medical Devices, Dr. Sato, Director of Division of Cell-Based Therapeutic Products, Dr. Kondo,
Director of Division of Biochemistry and Dr. Kanda, Director of Division of Pharmacology introduced specific research
outlines. These presentations were very interesting.

First clinical trial of products developedby Gene Therapy Research InstitutionCo., Ltd. In Japan starts
On October 17th, 2022, Gene therapy ResearchInstitution Co., Ltd. announced their developed
GT0002X targeting Parkinson’s disease was administrated to the patients at Jichi Medical University Hospital.
Aiming to improve long-term symptoms, thisclinical trial stimulates the release of dopamine
using a virus that is harmless to the human bodyto send genes to targeted areas in the brain. Goingforward, they plan to administrate the drug to
twelve patients at a rate of about one patient permonth and follow-up to investigate its safety andefficacy, with the aim of approving it as a newtreatment method.

【Deadline Dec.9】Cell culture training for“Monozukuri” companies
In life-science filed, along with development of technology anddiversity in R&D, a new development of culture devices, equipment, and use of technologies from different field are anticipated.
To facilitate this cell culture training will be held for“Monozukuri” companies who are interested in the life sciencesfield. It is an opportunity to understand how their technology
can be applied to the development needs of cell culture.
The presenters will be Kanagawa Prefecture who developed theLife Innovation Center which is a core center of industrialization of regenerative medicine ＆ cell therapy at KINGSSKYFRONT and Biotech Lab. which operates an open laboratory, Osaka Sanitary who conducts R&D and TONOMACHI
Life Science Cluster Division. We look forward to seeing as
many of you as possible at the training.
Click here for the details of the training

Hosted“Shared Labs Pitch! @ CIC x KING SKYFRONTOn September 21st, TONOMACHI Life Science Cluster Division jointly hosted a pitch event with CIC Tokyo,in which lab managers and life science start-ups joining shared labs presented and discussed the relationships between
the shared lab managers and start-ups.
“iCONM in collaboration with BioLabs” and Braizon Therapeutics from KINGSKYFRONT joined the event and talked about how shared lab works and what theadvantages of the Innovation Center of NanoMedicine (iCONM) facilities are.
To build an innovation ecosystem in Japan, lab facilities for experiments in the lifescience field is attracting more attention.
In particular, the "shared labs" is highly attractive since start-ups can start their experiments at that day with a minimum investment, by sharing lab space and equipment.
However, more shared labs are still required in Japan. In the last session of the event,panelists from start-ups and lab managers discussed how to create an innovation ecosystem from shared labs in a local area”, and the discussion was involved with audiences and the event was very exciting.
Recruitment of users of the shared office

For subscription“TONOMACHI Connect”

画像

If you are willing to have a base for your activities
in KING SKYFRONT, please consider doing so.

Keep you updated with the latest news from KINGSKYFRONT

Please apply here for subscription. i-Newsletter comes out
We are now accepting applications for the KING SKYFRONT
quarterly and free subscription.
share office "Tonomachi Connect" located in the Research Gate
Building II. Please consider if you are interested in having a base Date of issue: November 2022
your activities in KING SKYFRONT.
Publisher: Kawasaki Institute of Industrial Promotion
From November, the opening hours will be extended to 10:00
Mail：info-ksfcl@kawasaki-net.ne.jp
pm on weekdays and 6:00 pm on Saturdays. (Closed on Sundaysand public holidays)